YOLFTbeta
31

Level Biotechnology

3118 · TWO · Healthcare / Biotechnology

30.00TWD-0.20 (-0.66%)

Price History

Full chart

Market Stats

Previous Close30.20
Open30.15
Day Range29.95 – 30.45
52-Week Range30.75 – 34.70
Volume20.54K
Market Cap1.02B
P/E (TTM)13.54
Forward P/E0.00
EPS2.33
Dividend Yield7.03%
Beta0.23
50-Day Avg31.60
200-Day Avg32.62

About

Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. The company was founded in 1989 and is headquartered in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOJia-Xian Ye
  • Employees128
  • HeadquartersNo. 80, Kangning Street, New Taipei City, Taiwan, 221, Taiwan
  • Websitehttps://www.level.com.tw

Leadership

  • Jia-Xian YeManager
  • Yihan LiAccounting Supervisor

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue577.63M629.03M638.90M672.49M677.28M593.01M660.61M731.35M736.59M
Growth (%)-+8.90%+1.57%+5.26%+0.71%-12.44%+11.40%+10.71%+0.72%
Cost of Revenue369.70M443.52M443.10M460.78M444.77M390.42M441.07M494.22M478.89M
Gross Profit207.93M185.50M195.80M211.71M232.50M202.59M219.54M237.13M257.70M
Gross Margin36.00%29.49%30.65%31.48%34.33%34.16%33.23%32.42%34.99%
Operating Expense127.14M136.34M139.36M138.58M147.10M129.09M140.32M161.87M174.18M
Operating Income80.79M49.16M56.45M73.14M85.40M73.50M79.22M75.26M83.52M
Operating Margin13.99%7.82%8.83%10.88%12.61%12.40%11.99%10.29%11.34%
EBITDA95.86M65.58M80.17M93.96M105.19M93.00M98.95M102.62M120.23M
EBITDA Margin16.60%10.43%12.55%13.97%15.53%15.68%14.98%14.03%16.32%
Net Income68.31M38.91M47.40M58.04M68.18M58.47M62.91M64.81M79.70M
Net Income Margin11.83%6.19%7.42%8.63%10.07%9.86%9.52%8.86%10.82%
R&D11.88M13.63M13.64M13.70M15.02M14.03M13.77M12.95M13.70M
R&D as % of Total Revenue2.06%2.17%2.13%2.04%2.22%2.37%2.08%1.77%1.86%
Interest Expense00469.00K434.00K378.00K348.00K332.00K280.00K200.00K
Interest Expense % of Total Revenue0.00%0.00%0.07%0.06%0.06%0.06%0.05%0.04%0.03%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets732.31M680.39M750.18M772.99M787.62M812.53M822.67M827.11M866.80M
Total Liabilities210.03M181.60M236.43M243.56M242.78M270.13M273.20M267.19M286.63M
Total Equity522.28M498.78M513.75M529.43M544.84M542.40M549.47M559.91M580.18M
Cash320.76M272.78M344.42M380.32M472.95M463.50M467.41M252.78M210.34M
Total Debt---15.88M13.36M12.73M13.50M--
Net Debt----364.44M-459.59M-450.76M-453.90M--

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow71.29M26.77M109.02M83.23M155.95M65.07M70.21M64.10M59.61M
Investing Cash Flow-26.96M-13.05M-2.90M-2.63M-8.79M-10.19M---
Financing Cash Flow-61.66M-61.71M-34.48M-44.69M-54.52M-64.34M-55.40M--
Capital Expenditure10.83M2.51M2.43M2.54M9.15M6.74M7.67M223.68M32.67M
Free Cash Flow62.55M24.26M106.60M80.69M146.79M58.33M62.54M-159.58M26.94M
Dividends Paid61.66M61.66M32.45M42.19M51.92M61.66M55.17M55.17M58.41M
FCF to OCF87.74%90.62%97.77%96.95%94.13%89.64%89.08%-248.97%45.19%
Dividend Paid to FCF98.58%254.15%30.44%52.29%35.37%105.70%88.21%-34.57%216.84%

Earnings

Report DateMar 31, 2008Jun 30, 2008Sep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-------------------------------------------------------------
EPS Actual0.540.770.310.300.330.190.430.520.440.730.490.560.440.630.140.640.330.480.320.490.440.440.430.670.480.550.460.870.480.640.620.670.470.380.340.750.540.660.270.630.180.310.300.400.240.440.360.410.240.450.440.650.560.480.570.480.340.520.410.530.50
Surprise-------------------------------------------------------------
Timing-------------------------------------------------------------

Key Statistics & Ratios

Market Cap1.02B
Enterprise Value831.02M
Trailing P/E13.54
Forward P/E0.00
Price / Sales1.44
Price / Book1.89
EPS2.33
Book Value16.63
Revenue (TTM)709.37M
Gross Profit (TTM)257.14M
EBITDA102.77M
Profit Margin10.72%
Operating Margin7.36%
Return on Equity14.14%
Return on Assets6.48%
Shares Outstanding32.45M
Shares Float21.73M
Beta0.23
Dividend Yield7.03%
Dividend Rate2.20
Payout Ratio94.42%

Dividends

20261×
2.20Jun 10, 2026
20251×
1.80Jun 12, 2025
20241×
1.70Jun 18, 2024
20231×
1.70Jun 15, 2023
20221×
1.90Jun 17, 2022
20211×
1.60Jul 26, 2021
20201×
1.30Jun 16, 2020
20191×
1.00Jul 3, 2019
20181×
1.90Jun 28, 2018
20171×
1.90Jun 29, 2017
20161×
2.20Jun 29, 2016
20151×
2.00Jun 26, 2015
20141×
1.70Jul 2, 2014
20131×
1.70Jun 26, 2013
20121×
2.00Jun 27, 2012
20111×
1.43Aug 5, 2011
20101×
1.43Jun 30, 2010
20091×
1.71Jun 30, 2009

Stock Splits

  • Aug 5, 20111.05:1